Eisai and Lilly were the biggest winners at the 19^th Annual Scrip Awards in a glittering ceremony at the Dorchester in London’s Mayfair, hosted by the actor and comedian Jon Culshaw.

Under sponsor's current timetable, a single, two-part trial for pralatrexate and belinostat would not complete until 2030, resulting in respective delays of 21 and 16 years in confirming or refuting clinical benefit following accelerated approval. ODAC will discuss Acrotech’s delayed confirmatory trial program on 16 November.

CEO Pascal Soriot fielded questions on a wide range of topics – from China to US Medicare drug price negotiations – at a media briefing in New York City.

The company licensed an oral GLP-1 agonist from Eccogene, hoping to capitalize on its heritage in cardiovascular disease. AstraZeneca also reported third quarter results.